]Use of funds
The proceeds from the Entitlement Offer will be used to fund the ongoing Phase 2 ACCENT trial in
pancreatic cancer to an Interim Analysis (expected in Q3 2024), as well as undertake production of
additional narmafotinib capsules and support a pilot Investigator Initiated trial in ovarian cancer
currently in planning.
To my best understanding and guess, another CR will occur after Interim Analysis ...hopefully at a decent price. Also as mentioned by another poster... R&D rebate should kick-in in October. Blue sky ahead if interim results confirm the efficacy.
]Use of fundsThe proceeds from the Entitlement Offer will be...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.038(61.3%) |
Mkt cap ! $27.42M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 10.0¢ | 7.0¢ | $328.8K | 3.969M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13700 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 24649 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| ATX (ASX) Chart |